Stockreport

Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity [Seeking Alpha]

Soligenix, Inc.  (SNGX) 
NASDAQ:AMEX Investor Relations: soligenix.com/investors
PDF SummarySoligenix announced positive preliminary results from its phase 3 study using SGX301 to treat patients with cutaneous T-cell lymphoma.With 8-week preliminary data [Read more]